EMA firms up on how public hearings on marketed drugs will be run
This article was originally published in SRA
Executive Summary
The European Medicines Agency is inviting feedback on how its pharmacovigilance committee, the PRAC, should organize and conduct the public hearings that the committee is planning to hold as part of certain safety reviews of medicines1,2. The hearings would open the process of assessing medicines in the EU to the public for the first time3.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.